Xilio Therapeutics Long Term Debt

Xilio Therapeutics (XLO) currently reports a long-term debt of $4.9M as of June 2026. That compares with $6.3M in the prior-year period — down 22.6% year over year. Use the charts on this page to explore Xilio Therapeutics's long-term debt history and peer comparisons.

Xilio Therapeutics's long-term debt decreased from $6.3M to $4.9M — a 22.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Xilio Therapeutics reported $4.9M in long-term debt as of June 2026. That compares with $6.3M in the prior-year period — down 22.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $4.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Xilio Therapeutics, and consider following XLO for alerts when major investors trade the stock.

Xilio Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $4.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XLO with unrelated industries.